Alzheimer‘s Disease

By 2050, 138 million people may have dementia.¹ Screening for Alzheimer’s Disease and differentiating it from other dementia forms will be essential to patient care.

1 in 5 Alzheimer’s cases may be misdiagnosed.² Alzheimer's disease is often misdiagnosed, possibly causing undue stress for those who don't have the disease but are told they do, and delays in treatment for others.

New disease modifying therapies for Alzheimer's disease have emerged. However, the rate of incidence of their well known side effect, Amyloid Related Imaging Abnormalities (ARIA), was 10-30% in clinical trials.³ Therapeutic monitoring will be key to patient safety.

Our BIOGRAPH family of PET/CT and PET/MR scanners are crucial in evaluating amyloid plaques burden in the brain. PETNET Solutions provides specialized tracers that bind to amyloid plaques, confirming their presence. This confirmation helps physicians to identify Alzheimer's at an early stage. As visual assessment alone can be challenging for interpreting amyloid clinical cases syngo.via MI Neurology offers a powerful software with Cortical Analysis that encompasses SUVr and Centiloid to aid physicians in evaluating amyloid plaques.

MRI plays a key role in managing patients along the Alzheimer’s disease pathway. New pharmaceutical treatments require MRI scans at defined timepoints to follow-up for signs of ARIA (amyloid related imaging abnormalities), known side effects associated with these new treatments.^1,8  Every MAGNETOM scanner in our MR portfolio is equipped, out-of-the-box, to handle the scan requirements mandated by these novel therapies. AI-powered ^1,8 technologies such as myExam Brain Assist, Deep Resolve Boost, Sharp and Swift Brain is supposed to make sure that the scans are fast, automated, and reproducible. AI-Rad Companion Brain MR automates the visualization of anatomy and abnormalities in the brain.